Eddie Hickman
Stock Analyst at Guggenheim
(3.48)
# 895
Out of 4,944 analysts
16
Total ratings
43.75%
Success rate
10.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $51.36 | +63.55% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.70 | +757.14% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $11.76 | +87.07% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $12.14 | +163.59% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $7.63 | +358.72% | 1 | Mar 13, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $2.09 | +474.16% | 3 | Jan 17, 2025 |
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $51.36
Upside: +63.55%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.70
Upside: +757.14%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $11.76
Upside: +87.07%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $12.14
Upside: +163.59%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $7.63
Upside: +358.72%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $2.09
Upside: +474.16%